Download PDF
Viszeralchirurgie 2002; 37(2): 127-130
DOI: 10.1055/s-2002-25175
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Axilläre Dissektion versus Sentinel-Lymphknotenbiopsie - nicht konkurrierende, sondern ergänzende Verfahren in der Therapie des Mammakarzinoms

Axillary lamph node dissection vs. sentinel lymph node biopsy - not alternative but complementary concepts in the therapy of breast cancerA.  Bembenek, A.  U.  Liebeskind, P.  M.  Schlag
  • 1Klinik für Chirurgie und Chirurgische Onkologie, Universitätsklinikum Charité, Campus Buch,
    Robert-Rössle-Klinik im HELIOS Klinikum Berlin
Further Information

Publication History

Publication Date:
18 April 2002 (online)

    Permissions and Reprints

Zusammenfassung

Die Axilladissektion stellt einen allgemeinen Standard in der operativen Therapie des invasiven Mammakarzinoms dar. Die wichtigsten hierdurch verfolgten Ziele sind die Bestimmung des Lymphknotenstatus, eine Verbesserung der lokoregionären Tumorkontrolle und konsekutiv damit auch des Überlebens der Patienten [1]. Mit der Sentinel-Lymphknoten-Biopsie wird eine Individualisierung der Therapie angestrebt, ohne die Ziele der ALND außer Acht zu lassen [2]. Nachfolgend sollen die Vor- und Nachteile der beiden Vorgehensweisen und deren Einbindungsmöglichkeiten in ein modernes multimodales Konzept aufgezeigt werden.

Abstract

Axillary lymph node dissection (ALND) is a therapeutic standard in the operative therapy of invasive breast cancer. The major goals of ALND are the determination of the nodal status, local tumor control and the potentially resulting improvement of disease-free survival. The introduction of the sentinel lymph node biopsy in the therapeutic concept is one step further into the individualization of therapy without neglecting the goals of ALND. In the following, the advantages of both methods are discussed in the context of an interdisciplinary approach.

Schlüsselwörter

Sentinel Lymphknoten - Axilladissektion - Sentinel Lymphknotenbiopsie - Brustkrebs - Mammakarzinom - multimodale Therapie

Key words

Sentinel lymph node - sentinel lymph node biopsy - breast cancer - carcinoma of the breas - axillary lymph node dissection - interdisciplinary therapy

Literatur

  • 1 Bembenek A, Schlag P M. Lymph node dissection in breast cancer.  Langenbeck's Arch Surg. 1999;  385 236-245
    PubMedGoogle Scholar
  • 2 Schlag P M. Sentinel Lymphknoten Biopsie. Landsberg; ecomed Verlagsgesellschaft 2001
  • 3 Graversen H P, Blichert-Toft M, Andersen J A, Zedeler K. Danish Breast Cancer Cooperative Group . Breast cancer: risk of axillary recurrence in nodal-negative patients following partitial dissection of the axilla.  Eur J Surg Oncol. 1988;  14 407-412
    PubMedGoogle Scholar
  • 4 International Breast Cancer Study Group . Prognostic importance of occult axillary lymph node micrometastases from breast cancers.  Lancet. 1990;  335 1565-1568
    PubMedGoogle Scholar
  • 5 Cote J R, Peterson H F, Chaiwun P, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer.  Lancet. 1999;  354 896-900
    CrossrefPubMedGoogle Scholar
  • 6 Turner R R, Ollila D S, Krasne D L, Giuliano A E. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.  Ann Surg. 1997;  226 271-278
    CrossrefPubMedGoogle Scholar
  • 7 Chu K U, Turner R R, Hansen N M, Brennan M B, Bilchik A, Giuliano A E. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?.  Ann Surg. 1999;  229 536-541
    CrossrefPubMedGoogle Scholar
  • 8 van Diest P J, Torrenga H, Meijer S, Meijer C JLM. Pathological analysis of sentinel lymph nodes.  Sem Surg Oncol. 2001;  20 238-245
    PubMedGoogle Scholar
  • 9 Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series.  J Natl Cancer Inst. 1999;  91 368-373
    CrossrefPubMedGoogle Scholar
  • 10 Bembenek A, Reuhl T, Markwardt J, Schneider U, Schlag P M. Sentinel lymph node dissection in breast cancer.  Swiss Surg. 1999;  5 217-221
    PubMedGoogle Scholar
  • 11 McMasters K M, Wong S L, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph nodde biopsy: A model for implementation of new surgical techniques.  Ann Surg. 2001;  234 292-300
    CrossrefPubMedGoogle Scholar
  • 12 Van der Ent F WC, Kengen R AM, Van der Pool H AG, Povel J AC, Stroeken H JG, Hoofwijk A GM. Halsted revisited: Internal mammary sentinel lymph node Biopsy in breast cancer.  Ann Surg. 2001;  234 79-84
    CrossrefPubMedGoogle Scholar
  • 13 Byrd D B, Dunnwald L K, Mankoff D A, et al. Internal mammary lymph node drainage patterns in patients with breast cancer documented by lymphscintigraphy.  Ann Surg Oncol. 2001;  8 234-240
    PubMedGoogle Scholar
  • 14 Borgstein P J, Meijer S, Pijpers R J, van Diest P J. Functional lymphatic anatomy for sentinel node biopsy in breast cancer. Echoes from the past and the periareolar blue method.  Ann Surg. 2000;  232 81-89
    CrossrefPubMedGoogle Scholar
  • 15 Fischer B, Redmond C, Fisher E R, et al. Ten-year results of a randomized clinical trial comapring radical mastectomy and total mastectomy with or without radiation.  N Engl J Med. 1985;  312 674-681
    PubMedGoogle Scholar
  • 16 Osborne M P, Ormiston N, Harmer C L, McKinna J A, Baker J, Greening P. Breast conservation in the treatment of early breast cancer.  Cancer. 1984;  53 349-355
    PubMedGoogle Scholar
  • 17 Orr R K. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis.  Ann Surg Oncol. 1999;  6 109-116
    CrossrefPubMedGoogle Scholar
  • 18 Bland K I, Scott-Conner C E, Menck H, Winchester D P. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: A national cancer data base study of patterns of commission and implications for survival.  J Am Coll Surg. 1999;  188 586-596
    CrossrefPubMedGoogle Scholar
  • 19 Shetty M R, Reiman H M. Tumor size and axillary metastases, a correlation occurrence in 1244 cases of breast cancer between 1980 and 1995.  Eur J Surg Oncol. 1997;  23 139-141
    CrossrefPubMedGoogle Scholar
  • 20 Ververs J M, Roumen R M, Vingerhoets A J, Vreugdenhil G, Coebergh J W, Crommelin M A, Luiten E J, Repelaer van Driel O J, Schijven M, Wissing J C, Voogd A C. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.  Europ J Cancer. 2001;  37 (8) 991-999
    CrossrefPubMedGoogle Scholar
  • 21 Petrek J A, Senie R T, Peters M, Rosen P P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.  Cancer. 2001;  92 (6) 1368-1377
    CrossrefPubMedGoogle Scholar
  • 22 Kuehn T, Vogl F D, Pueckler S, et al. Sentinel node biopsy in breast cancer - technical performance is more important than patient selection to avoid false-negative findings.  Eur J Cancer. 2001;  37 Abstract 994
    PubMedGoogle Scholar
  • 23 Sener S F, Winchester D J, Martz C H, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma.  Cancer. 2001;  92 748-752
    CrossrefPubMedGoogle Scholar
  • 24 Early Breast Cancer Trialists Collaborative Group . Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer.  N Engl J Med. 1988;  319 1681-1692
    CrossrefPubMedGoogle Scholar
  • 25 Dees E C, Shulman L N, Souba W W, Smith B L. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer?.  Ann Surg. 1997;  226 279-287
    CrossrefPubMedGoogle Scholar
  • 26 Goldhirsch A, Glick J H, Gelber R D, Senn H J. International consensus panel on the treatment of primary breast cancer: V: update 1998.  Rec Res Cancer Res. 1998;  152 481-497
    PubMedGoogle Scholar
  • 27 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Senn H J. Meeting highlights: International Consensus Panel on the treatment of primary Brest cancer: Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.  J Clin Oncol. 2001;  19 3817-3827
    PubMedGoogle Scholar
  • 28 Levine M N, Bramwell V H, Pritchard K I, Norris B D, Shepherd L E, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Ottaway J, Burnell M, Williams C K, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 1998;  16 (8) 2651-2658
    CrossrefPubMedGoogle Scholar
  • 29 Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber R D, Coates A S. Taxanes as adjuvant for breast cancer.  Lancet. 2000;  356 (9228) 507-508
    CrossrefPubMedGoogle Scholar
  • 30 Ragaz J, Jackson S M, Plenderleith I H, Spinelli J J, Basco V E, Wilson K S, Knowling M A, Coppin C ML, Paradis M, Coldman A J, Olivotto I A. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.  New Engl J Med. 1997;  337 956-962
    CrossrefPubMedGoogle Scholar
  • 31 Dowlatsahi K, Fan M, Anderson J M, Bloem K J. Occult metastases in sentinel nodes of 200 patients with operable breast cancer.  Ann Surg Oncol. 2001;  8 675-682
    PubMedGoogle Scholar
  • 32 Ross M I. Sentinel node dissection in early-stage breast cancer: Ongoing prospective randomized trials in the USA.  Ann Surg Oncol. 2001;  8 77-81
    PubMedGoogle Scholar

Prof. Dr. Dr. h.c. P. M. Schlag

Klinik für Chirurgie und Chirurgische Onkologie, Universitätsklinikum Charité, Campus Buch, Robert-Rössle-Klinik im HELIOS Klinikum Berlin

Lindenberger Weg 80

13125 Berlin

Phone: + 49-30-9417-1400

Fax: + 49-30-9417-1404

Email: schlag@rrk-berlin.de

      >